# National Institute of Allergy and Infectious Diseases (NIAID): Early phase 1 study closed enrollment, 4 enrolled (Chronic Granulomatous Disease)

**Score:** 55/100

| Field | Value |
|---|---|
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Sponsor type | NIH |
| Study | Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide |
| NCT ID | NCT03910452 |
| Phase | Early phase 1 |
| Status | active not recruiting |
| Conditions | Chronic Granulomatous Disease |
| Intervention types | drug, radiation, biological |
| Target enrollment | 4 |
| Site countries | United States |
| Posted | 2019-04-10 |
| Planned start | 2019-10-28 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-29 |
| Last update posted | 2026-10-29 |

## Why this score
- Posted in the last two weeks.
- Enrollment closed: data management, monitoring and closeout ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT03910452). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.